Skip to main content
Equibles
ATYR logo

ATYR · aTYR PHARMA INC

Track ATYR — free

Use ATYR with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$0.50 +0.01 (+2.13%) At close · Sep 3
Rebalance outlook locked
Market Cap
$48.36M
Shares
98.09M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.50 Open$0.51 Day$0.48–0.51 52W close$0.40–6.03 Avg vol 30d643K Short int9.4M · 9.6% float · 14.7d Short vol52% Last earningsMar 13, 2025 DataJan 2020–Sep 2026 Filing10-Q · Aug 7

Up next

Latest filing: 10-Q
filed Aug 7, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$190,000
Trailing 12 months
Net income (TTM)
−$60.81M
Trailing 12 months
Revenue growth YoY
-19.1%
Year over year
Operating margin
-40,856.3%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-113.4%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+8.8%
Year over year · more shares
Price change (1Y)
-91.3%
Trailing year
Short interest
9.6%
Latest settlement · 14.7 days to cover
View all 114 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Poor Quant / Vol Very High
Market backdrop VIX 14.3 · calm Equity put/call 0.47
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −28%
below
Price vs 50-day avg −5%
below
RSI (14) 46
neutral
MACD trend Negative
52-week position 2%
near low
Momentum
relative strength
Very Weak
1-month return 0%
trailing
6-month return −41%
trailing
YTD return −36%
this year
Relative strength −58%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Distributing
-18% holders QoQ · +17 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
9.63% of float · ▼ -2.9% MoM · 14.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
93 holders — mid 3-yr range
Squeeze score 66
elevated · 0–100
Fundamentals
Poor
Revenue growth −19%
Y/Y
EPS growth +7%
Y/Y
Free cash flow $-62.1M
Quant / Vol
risk profile
Very High
Volatility 138%
annualized · 1-yr
Max drawdown −93%
past year
ATR 7.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
3 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−28% Bearish
Price vs 50-day avg
−5% Neutral
RSI (14)
46 Neutral
MACD trend
Negative Bearish
52-week position
2% Bearish
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Distributing
-18% holders QoQ · +17 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
9.63% of float · ▼ -2.9% MoM · 14.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
93 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $0 Now $1 · 2% Range high $6
vs 200-day avg -28% vs 50-day avg -5%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ATYR
aTYR PHARMA INC
this stock
$48.36M -35.7% -19.1% — 9.6%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $140.51B +23.1% +46.2% 32.3 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $84.82B +9.3% +20.8% 20.4 2.3%
ARGX
Argenx SE
 $65.63B +25.3% — — 1.9%
CSLLY
Csl Ltd
 $59.96B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
93
% held
40.4%
Net QoQ
-17.3M sh
Top holder
FEDERATED HERMES, INC.
Held Float
View
Held by Funds
Fund positions
57
View
Short & Settlement
Short Interest Falling
Shares short
9.4M
Days to cover
14.7d
Change
-284.7K sh
View
Short Volume
Short vol %
52%
As of
Sep 3, 2026
Short Total
View
Fails to Deliver
FTD shares
10.9K
Value
$5.8K
As of
Aug 11, 2026
View
Off-Exchange
Off-exchange %
66.8%
Week of
Jul 27, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$190.0K
Net income (FY)
$-74.1M
EPS diluted
$-0.80
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 7, 2026
This year
15
View
Earnings & Events
Earnings Calls
Last call
Jun 4, 2026
View

Performance

5D 20D 120D MTD YTD
ATYR -9.3% +0.3% -40.8% -5.4% -35.7%
SPY +0.3% +0.6% +16.7% +0.8% +13.4%
vs SPY -9.6% -0.3% -57.5% -6.2% -49.1%
Key facts CIK 1339970 CUSIP 002120202 13F (30d) 77 filings 76 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)